DOCSLIB.ORG

Table 2. Functional Classification of Genes Differentially Regulated After HOXB4 Inactivation in HSC/Hpcs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table 2. Functional Classification of Genes Differentially Regulated After HOXB4 Inactivation in HSC/Hpcs Table 2. Functional classification of genes differentially regulated after HOXB4 inactivation in HSC/HPCs Symbol Gene description Fold-change (mean ± SD) Signal transduction Adam8 A disintegrin and metalloprotease domain 8 1.91 ± 0.51 Arl4 ADP-ribosylation factor-like 4 - 1.80 ± 0.40 Dusp6 Dual specificity phosphatase 6 (Mkp3) - 2.30 ± 0.46 Ksr1 Kinase suppressor of ras 1 1.92 ± 0.42 Lyst Lysosomal trafficking regulator 1.89 ± 0.34 Mapk1ip1 Mitogen activated protein kinase 1 interacting protein 1 1.84 ± 0.22 Narf* Nuclear prelamin A recognition factor 2.12 ± 0.04 Plekha2 Pleckstrin homology domain-containing. family A. (phosphoinosite 2.15 ± 0.22 binding specific) member 2 Ptp4a2 Protein tyrosine phosphatase 4a2 - 2.04 ± 0.94 Rasa2* RAS p21 activator protein 2 - 2.80 ± 0.13 Rassf4 RAS association (RalGDS/AF-6) domain family 4 3.44 ± 2.56 Rgs18 Regulator of G-protein signaling - 1.93 ± 0.57 Rrad Ras-related associated with diabetes 1.81 ± 0.73 Sh3kbp1 SH3 domain kinase bindings protein 1 - 2.19 ± 0.53 Senp2 SUMO/sentrin specific protease 2 - 1.97 ± 0.49 Socs2 Suppressor of cytokine signaling 2 - 2.82 ± 0.85 Socs5 Suppressor of cytokine signaling 5 2.13 ± 0.08 Socs6 Suppressor of cytokine signaling 6 - 2.18 ± 0.38 Spry1 Sprouty 1 - 2.69 ± 0.19 Sos1 Son of sevenless homolog 1 (Drosophila) 2.16 ± 0.71 Ywhag 3-monooxygenase/tryptophan 5- monooxygenase activation protein. - 2.37 ± 1.42 gamma polypeptide Zfyve21 Zinc finger. FYVE domain containing 21 1.93 ± 0.57 Ligands and receptors Bambi BMP and activin membrane-bound inhibitor - 2.94 ± 0.62 Ccr2 Chemokine (C-C) receptor2 - 4.42 ± 3.36 Ccl9 Chemokine (C-C motif)ligand 9 - 2.11 ± 0.89 CD300lp CD300 antigen like family member B 2.71 ± 0.48 Dll1 Delta-like 1 - 2.91 ± 1.89 Gpr43 G protein-coupled receptor 43 1.89 ± 0.75 Icosl Icos ligand 2.83 ± 1.75 IL10rb Interleukin receptor beta 1.75 ± 0.44 IL15 Interleukin 15 2.21 ± 0.35 Ligands and receptors Mox2r* Antigen identified by monoclonal antibody MRc-OX-2 receptor 1.95 ± 0.14 Pde4dip Phosphodiesterase 4D interacting protein (myomegalin) 2.06 ± 0.43 Pdcd1lg1 Programmed cell death ligand 1 2.48 ± 0.97 Ptgir Prostaglandin I receptor 2.16 ± 0.97 Rora RAR-related orphan receptor 2.06 ± 0.62 Trl7 Toll-like receptor 7 2.15 ± 1.23 Tnfrsf1b Tumor necrosis factor receptor superfamily. member 1b 2.72 ± 1.47 Apoptosi s Bcl2l11 BCL2 like-11 2.45 ± 0.01 Bre Brain and reproductive organ expressed protein - 1.87 ± 0.53 Hspa1b* Heat shock protein 1b 16.8 ± 3.42 Serpina3g Serine ( or cysteine) protease inhibitor. clade A. member 3G - 1.73 ± 1.73 Tde1 Tumor differentially expressed 1 - 2.40 ± 1.20 Zfx Zinc finger protein X-linked - 1.93 ± 0.45 Cell adhesion/cytoskeleton Flnb Filamin beta 2.14 ± 0.68 Icam1 Intercellular adhesion molecule 1 2.54 ± 1.70 Msn Moesin - 2.03 ± 0.92 Pecam Platelet/endothelial cell adhesion molecule - 2.15 ± 0.09 Cell cycle Btg2 B-cell translocation gene 2 1.75 ± 0.91 Btg3 B-cell translocation gene - 2.37 ± 0.08 Cables Cdk5 and Abl enzyme substrate 1 2.13 ± 0.58 Cdkn1a Cyclin-dependent kinase inhibitor 1A (p21) 4.11 ± 0.55 Cdkn1b Cyclin-dependent kinase inhibitor 1B (p27) 1.80 ± 0.25 Ccng2 Cyclin G2 2.70 ± 1.53 Ccni * Cyclin I - 2.07 ± 0.42 Cnnm2 Cyclin M2 3.63 ± 2.90 Ddit3 DNA-damage inducible transcript 3 (Chop10; C/EBP-ζ) 2.42 ± 0.81 Fbxo9 F-box only protein 9 - 2.20 ± 0.45 Gadd45a Growth and DNAdamage inducible 45 alpha 1.65 ± 0.57 Mad Max dimerization protein 4.04 ± 1.56 Mcm3 Minichromosome maintenance deficient 3 - 1.79 ± 0.37 Regulation of transcription Catnb Catenin beta - 2.11 ± 0.64 Cebpb CCATT/enhancer binding protein (C/EBP) beta 1.95 ± 0.87 Crem* cAMP responsive element modulator 1.83 ± 0.61 Ddit4 DNA-damage inducible transcript 4 5.34 ± 2.66 Erg1 Early growth response - 2.24 ± 0.01 Etv5 Ets variant gene 5 - 1.99 ± 0.05 Foxo3a Forkhead box O3a 2.03 ± 0.41 Hbp1 High mobility group box trancription factor 1 1.72 ± 0.78 Icsbp1 Interferon consensus sequence binding protein 1 2.04 ± 0.95 Jundm2 Jun dimerization protein 2 2.17 ± 0.59 Klf3 Krüppel-like factor 3 2.48 ± 0.43 Mecp2 Methyl CpG binding protein 2 1.99 ± 0.63 Ncoa2 Nuclear receptor coactivator 2 1.88 ± 0.63 Nfe2 Nuclear factor. erythroid derived 2 2.05 ± 0.45 Nfe2l2 Nuclear factor. erythroid derived 2. like 2 - 2.54 ± 1.02 Nfkb2 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2. 1.97 ± 0.78 p49/100 Nfkbie* Nuclear factor of kappa light polypeptide gene enhancer in B-cells. 3.17 ± 2.05 inhibitor epsilon Nrip1 Nuclear receptor interacting protein 1 - 1.93 ± 0.59 Tcta T-cell leukemia translocation altered gene 2.13 ± 0.37 Tle1 Transducin-like enhancer of split 1 - 2.25 ± 0.51 Trim27 Tripartite motif 27 (ret finger protein) - 1.86 ± 0.28 Uhrf1 Ubiquitin-like. containing PHD and RING finger domains 1 - 1.80 ± 0.78 Zfp82 Zinc finger protein 82 2.09 ± 0.02 Zfp260 Zinc finger protein 260 1.95 ± 0.09 Zfp322a Zinc finger protein 322a 1.79 ± 0.32 Zfp192 Zinc finger protein 192 1.87 ± 0.18 RNA/DNA processing and translation Cirbp Cold inducible RNA binding protein - 2.05 ± 0.84 Cpeb2 Cytoplasmatic polyadenylation element binding protein 2 - 3.22 ± 2.40 Ddx3x DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3. X-linked - 2.64 ± 0.85 Eif4a1* Eukaryotic translation initiation factor 4A1 - 2.68 ± 1.35 Rad54b Rad54 homolog B (Fsbp) 1.88 ± 0.25 Sfrs5 Splicing factor. argenine/serine-rich 5 (SRp40;HRS) - 2.20 ± 0.17 Slfn8 Schalfen 8 2.11 ± 0.41 U2af1-rs U2 small nuclear ribonucleoprotein auxillary factor (U2AF) 1. related 1.74 ± 0.70 sequence 1 Carriers/transporter Abcg1 ATP-binding cassette. sub-family G(WHITE).member 1 1.90 ± 0.51 Slc7a11 Solute carrier family 7 (cationic amino acid transporter. y+ system). 1.97 ± 1.64 member 11 Slc16a6 Solute carrier family16(monocarboxylicacid transporters).member 16 - 2.85 ± 0.18 Enzymes Dgat1 Diacylglycerol O-acyltransferase 1 1.72 ± 0.57 Hmox1 Heme oxygenase (decycling) 1 2.43 ± 1.26 Mat2a Methionine adenosyltransferase II - 3.11 ± 1.96 Mgea5* Meningioma expressed antigen 5 (hyaluronidase) - 2.62 ± 0.09 P4ha1 Procollagen-proline. 2-oxoglutarate4-dioxygenase (proline 4- 1.85 ± 0.87 hydroxylase). alpha 1 polypeptide Ptgs2 Prostaglandin-endoperoxidase synthase 2 - 2.38 ± 1.01 Senp7 SUMO/sentrin specific protease 7 1.78 ± 0.38 Siat8d Sialyltransferase 8 (alpha-2. 8- sialyltransferase)D - 2.52 ± 1.30 Shmt1 Serine hydroxymethyl transferase 1 (soluble) - 1.87 ± 0.50 Others Herpud1 Homocysteine-inducible. endoplasmatic reticulum stress-inducible. 1.97 ± 0.71 ubiquitin-like domain member; Hist3h2a* Histone 3. H2a 6.11 ± 5.76 Hspa1a Heat shock protein 1a 3.33 ± 0.21 Irg1 Immunoresponsive gene 1 5.34 ± 5.62 Jmjd1a Jumonji domain containing 1 2.04 ± 0.20 Lpin1 Lpin 1 1.78 ± 0.58 Lrp2bp Lrp2 binding protein 4.92 ± 3.16 Lrrn3 Leucine rich repeat protein 3. neuronal - 2.82 ± 0.51 Mrpl15 Mitochondrial ribosomal protein L 15 - 2.21 ± 0.95 Obfc2a Oligonucleotide/oligosaccharide-binding fold containing 2A 2.40 ± 0.33 Osbpl5 Oxysterol binding protein-like 5 1.74 ± 0.58 Pck2 Phosphoenolpyruvate carboxykinase 2 (mitochondrial) 1.77 ± 0.35 Phf21a PHD finger protein 21A 1.85 ± 0.24 R3hdm1 R3H domain 1 (binds single-stranded nucleic acids) - 2.01 ± 0.13 Rnf135 Ring finger protein 135 1.84 ± 0.24 Others Rsad2 Radical S-adenosyl methionine domain containing 2 2.15 ± 0.43 Sart 2 Squamos cell carcinoma antigen recognized by T cells 2 - 2.22 ± 1.00 Smyd4 SET and MYND domain containing 4 1.76 ± 0.59 Spata 13 Spermatogenesis associated 13 2.04 ± 0.58 Tcta T-cell leukemia translocation altered gene 2.13 ± 0.37 Tex9 Testis expressed gene 9 1.77 ± 0.41 Thap2 THAP domain containing. apoptosis associated protein 2 2.04 ± 0.75 Tmem129 Transmembrane protein 129 2.07 ± 0.06 Tnfaip2* Tumor necrosis factor. alpha-induced protein 2 2.55 ± 1.54 Tnip1 TNFAIP3 interacting protein 1 2.62 ± 1.47 Wdr33 WD repeat domain 33 1.84 ± 0.32 Xist # Inactive X-specific transcripts -3.13 Fold change indicates the average change in gene expression 4 h after inactivation of HOXB4ER by tamoxifen- withdrawal in purified Lin -ckit +Sca +1HOXB4ER + cells relative to the associated LSKHOXB4-ER cells cultured in the presence of tamoxifen. Genes were selected based on their reproducibility in magnitude and direction in two independent HOXB4ER-transduced samples. A total of 133 known. unique genes are listed. and genes that were represented by more than one probeset/accession number are denoted by an asterisk (*). Functional annotations are based on Gene Ontology and Pubmed. #, A change in gene expression was only observed 1 h after tamoxifen withdrawal but not at later time points. .
Load more

Recommended publications
  • Functional Roles of Bromodomain Proteins in Cancer
    cancers Review Functional Roles of Bromodomain Proteins in Cancer Samuel P. Boyson 1,2, Cong Gao 3, Kathleen Quinn 2,3, Joseph Boyd 3, Hana Paculova 3 , Seth Frietze 3,4,* and Karen C. Glass 1,2,4,* 1 Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, VT 05446, USA; [email protected] 2 Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA; [email protected] 3 Department of Biomedical and Health Sciences, University of Vermont, Burlington, VT 05405, USA; [email protected] (C.G.); [email protected] (J.B.); [email protected] (H.P.) 4 University of Vermont Cancer Center, Burlington, VT 05405, USA * Correspondence: [email protected] (S.F.); [email protected] (K.C.G.) Simple Summary: This review provides an in depth analysis of the role of bromodomain-containing proteins in cancer development. As readers of acetylated lysine on nucleosomal histones, bromod- omain proteins are poised to activate gene expression, and often promote cancer progression. We examined changes in gene expression patterns that are observed in bromodomain-containing proteins and associated with specific cancer types. We also mapped the protein–protein interaction network for the human bromodomain-containing proteins, discuss the cellular roles of these epigenetic regu- lators as part of nine different functional groups, and identify bromodomain-specific mechanisms in cancer development. Lastly, we summarize emerging strategies to target bromodomain proteins in cancer therapy, including those that may be essential for overcoming resistance. Overall, this review provides a timely discussion of the different mechanisms of bromodomain-containing pro- Citation: Boyson, S.P.; Gao, C.; teins in cancer, and an updated assessment of their utility as a therapeutic target for a variety of Quinn, K.; Boyd, J.; Paculova, H.; cancer subtypes.
    [Show full text]
  • Cisplatin and Phenanthriplatin Modulate Long-Noncoding
    www.nature.com/scientificreports OPEN Cisplatin and phenanthriplatin modulate long‑noncoding RNA expression in A549 and IMR90 cells revealing regulation of microRNAs, Wnt/β‑catenin and TGF‑β signaling Jerry D. Monroe1,2, Satya A. Moolani2,3, Elvin N. Irihamye2,4, Katheryn E. Lett1, Michael D. Hebert1, Yann Gibert1* & Michael E. Smith2* The monofunctional platinum(II) complex, phenanthriplatin, acts by blocking transcription, but its regulatory efects on long‑noncoding RNAs (lncRNAs) have not been elucidated relative to traditional platinum‑based chemotherapeutics, e.g., cisplatin. Here, we treated A549 non‑small cell lung cancer and IMR90 lung fbroblast cells for 24 h with either cisplatin, phenanthriplatin or a solvent control, and then performed microarray analysis to identify regulated lncRNAs. RNA22 v2 microRNA software was subsequently used to identify microRNAs (miRNAs) that might be suppressed by the most regulated lncRNAs. We found that miR‑25‑5p, ‑30a‑3p, ‑138‑5p, ‑149‑3p, ‑185‑5p, ‑378j, ‑608, ‑650, ‑708‑5p, ‑1253, ‑1254, ‑4458, and ‑4516, were predicted to target the cisplatin upregulated lncRNAs, IMMP2L‑1, CBR3‑1 and ATAD2B‑5, and the phenanthriplatin downregulated lncRNAs, AGO2‑1, COX7A1‑2 and SLC26A3‑1. Then, we used qRT‑PCR to measure the expression of miR‑25‑5p, ‑378j, ‑4516 (A549) and miR‑149‑3p, ‑608, and ‑4458 (IMR90) to identify distinct signaling efects associated with cisplatin and phenanthriplatin. The signaling pathways associated with these miRNAs suggests that phenanthriplatin may modulate Wnt/β‑catenin and TGF‑β signaling through the MAPK/ ERK and PTEN/AKT pathways diferently than cisplatin. Further, as some of these miRNAs may be subject to dissimilar lncRNA targeting in A549 and IMR90 cells, the monofunctional complex may not cause toxicity in normal lung compared to cancer cells by acting through distinct lncRNA and miRNA networks.
    [Show full text]
  • Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice
    Loyola University Chicago Loyola eCommons Biology: Faculty Publications and Other Works Faculty Publications 2013 Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice Mihaela Palicev Gunter P. Wagner James P. Noonan Benedikt Hallgrimsson James M. Cheverud Loyola University Chicago, [email protected] Follow this and additional works at: https://ecommons.luc.edu/biology_facpubs Part of the Biology Commons Recommended Citation Palicev, M, GP Wagner, JP Noonan, B Hallgrimsson, and JM Cheverud. "Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice." Genome Biology and Evolution 5(10), 2013. This Article is brought to you for free and open access by the Faculty Publications at Loyola eCommons. It has been accepted for inclusion in Biology: Faculty Publications and Other Works by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. © Palicev et al., 2013. GBE Genomic Correlates of Relationship QTL Involved in Fore- versus Hind Limb Divergence in Mice Mihaela Pavlicev1,2,*, Gu¨ nter P. Wagner3, James P. Noonan4, Benedikt Hallgrı´msson5,and James M. Cheverud6 1Konrad Lorenz Institute for Evolution and Cognition Research, Altenberg, Austria 2Department of Pediatrics, Cincinnati Children‘s Hospital Medical Center, Cincinnati, Ohio 3Yale Systems Biology Institute and Department of Ecology and Evolutionary Biology, Yale University 4Department of Genetics, Yale University School of Medicine 5Department of Cell Biology and Anatomy, The McCaig Institute for Bone and Joint Health and the Alberta Children’s Hospital Research Institute for Child and Maternal Health, University of Calgary, Calgary, Canada 6Department of Anatomy and Neurobiology, Washington University *Corresponding author: E-mail: [email protected].
    [Show full text]
  • TRANSCRIPTIONAL REGULATION of Hur in RENAL STRESS
    TRANSCRIPTIONAL REGULATION OF HuR IN RENAL STRESS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Sudha Suman Govindaraju Graduate Program in Biochemistry The Ohio State University 2014 Dissertation Committee: Dr. Beth S. Lee, Ph.D., Advisor Dr. Kathleen Boris-Lawrie, Ph.D. Dr. Sissy M. Jhiang, Ph.D. Dr. Arthur R. Strauch, Ph.D Abstract HuR is a ubiquitously expressed RNA-binding protein that affects the post- transcriptional life of thousands of cellular mRNAs by regulating transcript stability and translation. HuR can post-transcriptionally regulate gene expression and modulate cellular responses to stress, differentiation, proliferation, apoptosis, senescence, inflammation, and the immune response. It is an important mediator of survival during cellular stress, but when inappropriately expressed, can promote oncogenic transformation. Not surprisingly, the expression of HuR itself is tightly regulated at multiple transcriptional and post-transcriptional levels. Previous studies demonstrated the existence of two alternate HuR transcripts that differ in their 5’ untranslated regions and have markedly different translatabilities. These forms were also found to be reciprocally expressed following cellular stress in kidney proximal tubule cell lines, and the shorter, more readily translatable variant was shown to be regulated by Smad 1/5/8 pathway and bone morphogenetic protein-7 (BMP-7) signaling. In this study, the factors that promote transcription of the longer alternate form were identified. NF-κB was shown to be important for expression of the long HuR mRNA, as was a newly identified region with potential for binding the Sp/KLF families of transcription factors.
    [Show full text]
  • Carbon Monoxide Prevents TNF-Α-Induced Enos Downregulation by Inhibiting NF-Κb-Responsive Mir-155-5P Biogenesis
    OPEN Experimental & Molecular Medicine (2017) 49, e403; doi:10.1038/emm.2017.193 Official journal of the Korean Society for Biochemistry and Molecular Biology www.nature.com/emm ORIGINAL ARTICLE Carbon monoxide prevents TNF-α-induced eNOS downregulation by inhibiting NF-κB-responsive miR-155-5p biogenesis Seunghwan Choi1, Joohwan Kim1, Ji-Hee Kim1, Dong-Keon Lee1, Wonjin Park1, Minsik Park1, Suji Kim1, Jong Yun Hwang2, Moo-Ho Won3, Yoon Kyung Choi1,4, Sungwoo Ryoo5, Kwon-Soo Ha1, Young-Guen Kwon6 and Young-Myeong Kim1 Heme oxygenase-1-derived carbon monoxide prevents inflammatory vascular disorders. To date, there is no clear evidence that HO-1/CO prevents endothelial dysfunction associated with the downregulation of endothelial NO synthesis in human endothelial cells stimulated with TNF-α. Here, we found that the CO-releasing compound CORM-2 prevented TNF-α-mediated decreases in eNOS expression and NO/cGMP production, without affecting eNOS promoter activity, by maintaining the functional activity of the eNOS mRNA 3′-untranslated region. By contrast, CORM-2 inhibited MIR155HG expression and miR-155-5p biogenesis in TNF-α-stimulated endothelial cells, resulting in recovery of the 3′-UTR activity of eNOS mRNA, a target of miR-155-5p. The beneficial effect of CORM-2 was blocked by an NF-κB inhibitor, a miR-155-5p mimic, a HO-1 inhibitor and siRNA against HO-1, indicating that CO rescues TNF-α-induced eNOS downregulation through NF-κB-responsive miR-155-5p expression via HO-1 induction; similar protective effects of ectopic HO-1 expression and bilirubin were observed in endothelial cells treated with TNF-α.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • In Acute Myeloid Leukemia
    7283 Original Article Comprehensively analyze the expression and prognostic role for ten-eleven translocations (TETs) in acute myeloid leukemia Yan Huang1#, Jie Wei1#, Xunjun Huang1, Weijie Zhou1, Yuling Xu2, Dong-Hong Deng2, Peng Cheng2 1Department of Hematology and Rheumatology, People’s Hospital of Baise, Baise, China; 2Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China Contributions: (I) Conception and design: J Wei, Y Huang; (II) Administrative support: X Huang, Y Xu; (III) Provision of study materials or patients: W Zhou; (IV) Collection and assembly of data: J Wei, Y Huang; (V) Data analysis and interpretation: DH Deng, P Cheng; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Yuling Xu. Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Email: [email protected]; Dong-Hong Deng. Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Email: [email protected]; Peng Cheng. Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530000, China. Email: [email protected]. Background: The ten-eleven translocation (TET) family oxidize 5-methylcytosines (5mCs) and promote the locus-specific reversal of DNA. The role of TETs in acute myeloid leukemia (AML) is mostly unknown. Methods: TETs mRNA expression levels were analyzed via Gene Expression Profiling Interactive Analysis (GEPIA). The association TETs expression levels and methylation with prognosis by UALCAN GenomicScape, and METHsurv. We analyzed TETs’ aberration types, located mutations, and structures via cBioPortal. GeneMANIA performed the functional network. Gene ontology (GO) enrichment was analyzed via LinkedOmics.
    [Show full text]
  • Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin
    cells Review Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin Agnieszka Bochy ´nska,Juliane Lüscher-Firzlaff and Bernhard Lüscher * ID Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Pauwelsstrasse 30, 52057 Aachen, Germany; [email protected] (A.B.); jluescher-fi[email protected] (J.L.-F.) * Correspondence: [email protected]; Tel.: +49-241-8088850; Fax: +49-241-8082427 Received: 18 January 2018; Accepted: 27 February 2018; Published: 2 March 2018 Abstract: Regulation of gene expression is achieved by sequence-specific transcriptional regulators, which convey the information that is contained in the sequence of DNA into RNA polymerase activity. This is achieved by the recruitment of transcriptional co-factors. One of the consequences of co-factor recruitment is the control of specific properties of nucleosomes, the basic units of chromatin, and their protein components, the core histones. The main principles are to regulate the position and the characteristics of nucleosomes. The latter includes modulating the composition of core histones and their variants that are integrated into nucleosomes, and the post-translational modification of these histones referred to as histone marks. One of these marks is the methylation of lysine 4 of the core histone H3 (H3K4). While mono-methylation of H3K4 (H3K4me1) is located preferentially at active enhancers, tri-methylation (H3K4me3) is a mark found at open and potentially active promoters. Thus, H3K4 methylation is typically associated with gene transcription. The class 2 lysine methyltransferases (KMTs) are the main enzymes that methylate H3K4. KMT2 enzymes function in complexes that contain a necessary core complex composed of WDR5, RBBP5, ASH2L, and DPY30, the so-called WRAD complex.
    [Show full text]
  • A Conserved Gene Family Encodes Transmembrane Proteins with Fibronectin, Immunoglobulin and Leucine-Rich Repeat Domains (FIGLER) Delicia L
    A conserved gene family encodes transmembrane proteins with fibronectin, immunoglobulin and leucine-rich repeat domains (FIGLER) Delicia L. Munfus, University of Alabama at Birmingham Christopher L. Haga, University of Alabama at Birmingham Peter D. Burrows, University of Alabama at Birmingham Max Cooper, Emory University Journal Title: BMC Biology Volume: Volume 5, Number 1 Publisher: BioMed Central | 2007-09-13, Pages 36-36 Type of Work: Article | Final Publisher PDF Publisher DOI: 10.1186/1741-7007-5-36 Permanent URL: https://pid.emory.edu/ark:/25593/rqdhh Final published version: http://dx.doi.org/10.1186/1741-7007-5-36 Copyright information: © 2007 Munfus et al; licensee BioMed Central Ltd. This is an Open Access work distributed under the terms of the Creative Commons Attribution 2.0 Generic License (http://creativecommons.org/licenses/by/2.0/). Accessed October 6, 2021 6:19 AM EDT BMC Biology BioMed Central Research article Open Access A conserved gene family encodes transmembrane proteins with fibronectin, immunoglobulin and leucine-rich repeat domains (FIGLER) Delicia L Munfus†1,2, Christopher L Haga†1,2, Peter D Burrows1,2,3 and Max D Cooper*1,2,4,5 Address: 1Division of Developmental and Clinical Immunology, University of Alabama at Birmingham, Birmingham, AL 35294-3300, USA, 2Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294-3300, USA, 3Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294-3300,, 4Department of Medicine, University of Alabama at Birmingham, Birmingham,
    [Show full text]
  • Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers
    Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers Jiancheng Hu,1,2 Edward C. Stites,1 Haiyang Yu,1 Elizabeth A. Germino,1 Hiruy S. Meharena,3,4 Philip J.S. Stork,6 Alexandr P. Kornev,3,4,5 Susan S. Taylor,3,4,5,* and Andrey S. Shaw1,2,* 1Department of Pathology and Immunology 2Howard Hughes Medical Institute Washington University School of Medicine, 660 South Euclid, Box 8118, St. Louis, MO 63110, USA 3Department of Chemistry/Biochemistry 4Department of Pharmacology 5Howard Hughes Medical Institute University of California San Diego, 9500 Gilman Drive, Mail code 0654, La Jolla, CA 92093, USA 6Vollum Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA *Correspondence: [email protected] (S.S.T.), [email protected] (A.S.S.) http://dx.doi.org/10.1016/j.cell.2013.07.046 SUMMARY There are three isoforms of RAF: A-RAF, B-RAF, and C-RAF. Each appears to have a distinct mechanism of activation (Baljuls Although RAF kinases are critical for controlling et al., 2007; Galabova-Kovacs et al., 2006; Wimmer and Baccar- cell growth, their mechanism of activation is incom- ini, 2010). BRAF is considered to be more active and have a pletely understood. Recently, dimerization was simpler mechanism of activation in comparison to CRAF and shown to be important for activation. Here we show ARAF (Chong et al., 2001; Rebocho and Marais, 2013; Zhang that the dimer is functionally asymmetric with one and Guan, 2000). This difference can potentially explain why kinase functioning as an activator to stimulate activ- BRAF mutations are so common in cancer, in contrast to CRAF and ARAF, where mutations are rarely found (Davies ity of the partner, receiver kinase.
    [Show full text]
  • 0.5) in Stat3∆/∆ Compared with Stat3flox/Flox
    Supplemental Table 2 Genes down-regulated (<0.5) in Stat3∆/∆ compared with Stat3flox/flox Probe ID Gene Symbol Gene Description Entrez gene ID 1460599_at Ermp1 endoplasmic reticulum metallopeptidase 1 226090 1460463_at H60c histocompatibility 60c 670558 1460431_at Gcnt1 glucosaminyl (N-acetyl) transferase 1, core 2 14537 1459979_x_at Zfp68 zinc finger protein 68 24135 1459747_at --- --- --- 1459608_at --- --- --- 1459168_at --- --- --- 1458718_at --- --- --- 1458618_at --- --- --- 1458466_at Ctsa cathepsin A 19025 1458345_s_at Colec11 collectin sub-family member 11 71693 1458046_at --- --- --- 1457769_at H60a histocompatibility 60a 15101 1457680_a_at Tmem69 transmembrane protein 69 230657 1457644_s_at Cxcl1 chemokine (C-X-C motif) ligand 1 14825 1457639_at Atp6v1h ATPase, H+ transporting, lysosomal V1 subunit H 108664 1457260_at 5730409E04Rik RIKEN cDNA 5730409E04Rik gene 230757 1457070_at --- --- --- 1456893_at --- --- --- 1456823_at Gm70 predicted gene 70 210762 1456671_at Tbrg3 transforming growth factor beta regulated gene 3 21378 1456211_at Nlrp10 NLR family, pyrin domain containing 10 244202 1455881_at Ier5l immediate early response 5-like 72500 1455576_at Rinl Ras and Rab interactor-like 320435 1455304_at Unc13c unc-13 homolog C (C. elegans) 208898 1455241_at BC037703 cDNA sequence BC037703 242125 1454866_s_at Clic6 chloride intracellular channel 6 209195 1453906_at Med13l mediator complex subunit 13-like 76199 1453522_at 6530401N04Rik RIKEN cDNA 6530401N04 gene 328092 1453354_at Gm11602 predicted gene 11602 100380944 1453234_at
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]